Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Key takeaways
- While both operate within the same broader sector, their business models differ significantly.
- Bristol Myers operates as a major player in the pharmaceutical stocks space, focusing on oncology, hematology, and immunology.
- In fiscal 2025, revenue reached nearly $48.2 billion, reflecting a slight decrease of approximately 0.2% compared to the previous year.
BMY JNJ MRK Choosing between Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) means deciding whether you prefer a pure-play pharmaceutical company trading at a deep discount or a diversified giant with higher growth.
While both operate within the same broader sector, their business models differ significantly. Bristol Myers focuses heavily on drug development for serious diseases, while Johnson & Johnson splits its attention between medicine and medical devices. Let's compare them and weigh their specific risks and financial health.
Bristol Myers operates as a major player in the pharmaceutical stocks space, focusing on oncology, hematology, and immunology. The company sells its innovative medicines primarily to wholesalers and specialty pharmacies, relying on established distribution channels for top products like Opdivo and Eliquis. Key commercial alliances with Merck (NYSE:MRK) and BioNTech (NASDAQ:BNTX) help Bristol Myers expand its reach in specialized therapeutic areas.